Table 3.
Baseline patient characteristics and salvage prostatectomy outcomes.
| Value | |
|---|---|
| Median age at time of sRP (yrs) | 65 (range 61–67) |
| Time from primary treatment to sRP (mo) | 24 (range 11–61) |
| Median follow up (mo) | 27 (range 10–62) |
| Type of FT prior to sRP (n = 482) | |
| HIFU | 295 (61.2%) |
| Cryotherapy | 79 (16.4%) |
| VTP | 69 (14.3%) |
| Irreversible electroporation | 17 (3.5%) |
| Laser | 15 (3.1%) |
| PRX302 Topsalysin | 4 (0.8%) |
| Brachytherapy | 3 (0.6%) |
| Repeat ablation (n = 248) | |
| YES | 37 (14.9%) |
| NO | 211 (85.1%) |
| SRP type (n = 468) | |
| Robotic | 399 (85.3%) |
| Open | 60 (12.8%) |
| Laparoscopic | 9 (1.9%) |
| Nerve-sparing (n = 468) | |
| Unilateral | 145 (30.9%) |
| Bilateral | 115 (24.6%) |
| None | 208 (44.5%) |
| Pre-Preoperative sRP Biopsy (n = 482) * | |
| Grade Group I (3 + 3) | 84 (17.4%) |
| Grade Group II (3 + 4) | 216 (44.8%) |
| Grade Group III (4 + 3) | 119 (24.7%) |
| Grade Group IV (4 + 4) | 21 (4.4%) |
| Grade Group V (4 + 5, 5 + 4) | 17 (3.5%) |
| Missing | 9 (1.9%) |
| Postoperative outcomes | |
| Total number of complications (n = 482) | 59 (12.2%) |
| Clavien grade I | 24 (40.7%) |
| Clavien grade II | 13 (22.0%) |
| Clavien grade IIIa | 7 (11.9%) |
| Clavien grade IIIb | 14 (23.7%) |
| Clavien grade IV | 1 (1.7%) |
| Clavien grade V | 0 (0%) |
| Major complications (CG >3) (n = 482) | 18 (30.5%) |
| Oncologic outcomes (n = 482) | |
| Positive surgical margin | 126 (26.1%) |
| Biochemical recurrence | 118 (24.5%) |
| Postoperative sRP Biopsy (n = 482) * | |
| Grade Group I (3 + 3) | 40 (8.3%) |
| Grade Group II (3 + 4) | 215 (44.6%) |
| Grade Group III (4 + 3) | 134 (27.8%) |
| Grade Group IV (4 + 4) | 15 (3.1%) |
| Grade Group V (4 + 5, 5 + 4) | 27 (5.6%) |
| Missing | 1 (0.2%) |
| Functional outcomes | |
| Continence (12 mo) (n = 467) | 319 (68.3%) |
| Potency (12 mo) (n = 351) | 107 (30.5%) |
CG = Clavien grade, FT = focal therapy, HIFU = high-intensity focused ultrasound, sRP = salvage radical prostatectomy, VTP = vascular targeted photodynamic therapy. * One study, Onol et al., combined GG2-3 together (n = 20) and GG4-5 (n = 6) together for preop sRP biopsy. Similarly, they combined GG2-3 together (n = 23) and GG4-5 (n = 6) together for postop sRP specimen pathology.